S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.80 (+-0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.80 (+-0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.80 (+-0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.80 (+-0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
NASDAQ:CRDL

Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

$1.81
+0.01 (+0.56%)
(As of 10:39 AM ET)
Today's Range
$1.76
$1.88
50-Day Range
$1.02
$2.06
52-Week Range
$0.45
$2.17
Volume
72,390 shs
Average Volume
384,596 shs
Market Capitalization
$123.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Cardiol Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
66.7% Upside
$3.00 Price Target
Short Interest
Healthy
0.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Cardiol Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.30 out of 5 stars

Medical Sector

595th out of 939 stocks

Biological Products, Except Diagnostic Industry

100th out of 157 stocks

CRDL stock logo

About Cardiol Therapeutics Stock (NASDAQ:CRDL)

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

CRDL Stock Price History

CRDL Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
Cardiol Therapeutics Inc Class A CRDL
See More Headlines
Receive CRDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
3/28/2024
Next Earnings (Estimated)
5/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CRDL
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+66.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$60,000.00
Book Value
$0.63 per share

Miscellaneous

Free Float
64,590,000
Market Cap
$122.71 million
Optionable
Not Optionable
Beta
1.00
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. David G. Elsley MBA
    President, CEO & Director
  • Mr. Christopher J. Waddick C.A.
    C.M.A., CPA, CMA, MBA, CFO, Corporate Secretary & Director
  • Mr. Bernard Lim B.Sc.
    Chief Operating Officer
  • Dr. Andrew Warwick Hamer M.D. (Age 62)
    Chief Medical Officer & Head of Research & Development
    Comp: $366.2k
  • Trevor Burns
    Investor Relations

CRDL Stock Analysis - Frequently Asked Questions

Should I buy or sell Cardiol Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRDL shares.
View CRDL analyst ratings
or view top-rated stocks.

What is Cardiol Therapeutics' stock price target for 2024?

2 brokers have issued twelve-month target prices for Cardiol Therapeutics' stock. Their CRDL share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 66.7% from the stock's current price.
View analysts price targets for CRDL
or view top-rated stocks among Wall Street analysts.

How have CRDL shares performed in 2024?

Cardiol Therapeutics' stock was trading at $0.8432 on January 1st, 2024. Since then, CRDL shares have increased by 113.5% and is now trading at $1.80.
View the best growth stocks for 2024 here
.

Are investors shorting Cardiol Therapeutics?

Cardiol Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 273,000 shares, a drop of 24.4% from the February 29th total of 361,100 shares. Based on an average daily volume of 363,100 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.4% of the shares of the company are sold short.
View Cardiol Therapeutics' Short Interest
.

When is Cardiol Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024.
View our CRDL earnings forecast
.

How were Cardiol Therapeutics' earnings last quarter?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) issued its earnings results on Tuesday, November, 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02.

Who are Cardiol Therapeutics' major shareholders?

Cardiol Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include AdvisorShares Investments LLC (1.82%), AXS Investments LLC (1.07%), Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRDL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners